Apellis Pharmaceuticals (NASDAQ:APLS) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Friday, Benzinga reports. The firm currently has a $92.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. UBS Group upped their target price on Apellis […]

Related Keywords

China ,Mark Jeffrey Delong ,Pascal Deschatelets ,Robertw Baird ,China Universal Asset Management Co ,Stephens Consulting ,Apellis Pharmaceuticals Trading ,Covestor Ltd ,Nasdaq ,Apellis Pharmaceuticals ,Financial Wealth Managment ,Jpmorgan Chase Co ,News Ratings For Apellis Pharmaceuticals Daily ,Apellis Pharmaceuticals Inc ,Analyst Recommendations For Apellis Pharmaceuticals ,Needham Company ,First Horizon Advisors Inc ,Free Report ,Moderate Buy ,Get Free Report ,Horizon Advisors ,China Universal Asset Management ,Universal Asset Management ,Apellis Pharmaceuticals Daily ,Nasdaq Apls ,Apls ,Medical ,Reiterated Rating ,Hc Wainwright ,